Humanigen, Inc.

  1. April 16, 2024

    Retired Judge Carey Dies, Fraudster Charged, Diocese Bails

    The bankruptcy bench in Delaware lost a well-respected colleague, retired Judge Kevin J. Carey, while federal court officials made good on efforts to root out fraud in the nation's bankruptcy courts, and a New York Catholic diocese moved to end its Chapter 11 case without a reorganization plan after abuse claimants roundly rejected its proposal.

  2. April 15, 2024

    Humanigen Files Ch. 11 Plan Disclosures

    Bankrupt biopharma company Humanigen Inc. has filed a proposed Chapter 11 plan and disclosure statement in Delaware court that calls for the payment in full of secured and priority claims, while general unsecured creditors owed a collective $44 million will receive up to 19% recoveries.

  3. February 14, 2024

    Pharma Co. Humanigen Gets OK For Ch. 11 Sale

    Drug researcher Humanigen Inc. can sell nearly all of its assets to a company formed by its CEO, a Delaware bankruptcy judge ruled Wednesday, after the debtor, the buyer and the official committee of unsecured creditors struck a deal resolving objections to the Chapter 11 sale.

  4. February 13, 2024

    FDA, Creditors Oppose Drugmaker Humanigen's Ch. 11 Sale

    Biopharmaceutical company Humanigen faced fire on multiple fronts Tuesday after it asked the Delaware bankruptcy court to approve a $2 million stalking horse credit bid from its debtor-in-possession lender, an entity founded by the debtor's chief executive, that is opposed by the FDA and certain creditors.

  5. February 09, 2024

    Humanigen Creditors Say DIP Loan Ties Up Too Many Assets

    The official committee of unsecured creditors in the Chapter 11 case of Humanigen Inc. objected to the final approval of the company's debtor-in-possession loan, saying while the financing provides $2 million of new money, the lenders seek to put liens on all of the debtor's assets. 

  6. January 23, 2024

    Del. Judge Nixes Bidder Fees In Humanigen Ch. 11

    A Delaware bankruptcy judge Tuesday partially rejected bidding procedures for biopharmaceutical company Humanigen Inc.'s assets, saying a proposed $200,000 in bidding protections for the stalking horse bidder, which is also the DIP lender, was disproportionate to the $2 million purchase price.

  7. January 08, 2024

    Humanigen Gets Access To New Cash For Ch. 11 Process

    Biopharmaceutical company Humanigen Inc. received bankruptcy court approval Monday to access half of a $2 million debtor-in-possession loan to help fund its ongoing drug development operations and its Chapter 11 case.

  8. January 04, 2024

    Humanigen Hits Ch. 11 After COVID Drug Denied Authorization

    After failing to receive emergency authorization for a COVID-19 treatment, drug developer Humanigen Inc. filed for Chapter 11 bankruptcy in Delaware with $44.1 million in unsecured debt and plans to pursue a $2 million sale to an entity formed by its CEO.